Article
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.
Leukemia - 1 Jul 2012
Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater A P, Cymbalista F, Eichhorst B, Hallek M, Döhner H, Hillmen P, van Oers M, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T
Abstract excerpt
Recent evidence suggests that - in addition to 17p deletion - TP53 mutation is an independent prognostic factor in chronic lymphocytic leukemia (CLL). Data from retrospective analyses and prospective clinical trials show that ∼5% of untreated CLL patients with treatment indication have a TP53 mutation in the absence of 17p deletion. These patients have a poor response and reduced progression-free survival and...
Topics
- Chromosomes, Human, Pair 17
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
- Mutation
- Practice Guidelines as Topic
- Prognosis
- Tumor Suppressor Protein p53